San Diego-based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug industry in February after revealing promising details from a mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection and in March the company unveil